Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?

Peritoneal Dialysis International

Volumn 33, Issue 5, 2013, Pages 529-537

  Barreto, Deirisa Lopes ^a   Coester, Annemieke M ^a   Struijk, Dirk G ^a,b   Krediet, Raymond T ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Dianet Foundation   (Netherlands)

Author keywords

Biomarkers; Fibrosis; Matrix metalloproteinase 2; Peritoneal membrane; Plasminogen activator inhibitor type 1

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; DIABETIC NEPHROPATHY; DIALYSATE; DISEASE SEVERITY; EFFLUENT; FEMALE; FIBRIN FORMATION; FOLLOW UP; GLOMERULONEPHRITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE PERMEABILITY; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEAL FIBROSIS; PERITONEAL FLUID LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENOVASCULAR DISEASE; TREATMENT DURATION; TREATMENT OUTCOME;

BIOMARKERS; FIBROSIS; MATRIX METALLOPROTEINASE 2; PERITONEAL MEMBRANE; PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1;

ADOLESCENT; ADULT; AGED; ANIMALS; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PERMEABILITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; RATS; YOUNG ADULT;

EID: 84885760085     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2012.01063     Document Type: Article

References (40)

1. Nolph KD, Popovich RP, Ghods AJ, Twardowski Z. Determinants of low clearances of small solutes during peritoneal dialysis. Kidney Int 1978; 13:117-23.
2. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19:517-25.
3. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. on behalf of the Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
4. Sampimon DE, Coester AM, Struijk DG, Krediet RT. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2011; 26:291-8.
5. Smit W, Parikova A, Krediet RT. Ultrafiltration failure in peritoneal dialysis. Causes and clinical consequences. Minerva Urol Nefrol 2005; 57:165-74.
6. Smit W, Parikova A, Struijk DG, Krediet RT. The difference in causes of early and late ultrafiltration failure in peritoneal dialysis. Perit Dial Int 2005; 25(SUPPL 3):S41-5.
7. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21:560-7.
8. Sitter T, Spannagl M, Schiffl H, Held E, van Hinsbergh VW, Kooistra T. Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells. Nephrol Dial Transplant 1995; 10:677-83.
9. Loskutoff DJ, Sawdey M, Mimuro J. Type I plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9:87-115.
10. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95:105-17.
11. Vipond MN, Whawell SA, Thompson JN, Dudley HA. Peritoneal fibrinolytic activity and intra-abdominal adhesions. Lancet 1990; 335:1120-2.
12. Buckman RF, Woods M, Sargent L, Gervin AS. A unifying pathogenetic mechanism in the etiology of intraperitoneal adhesions. J Surg Res 1976; 20:1-5.
13. de Boer AW, Levi M, Reddingius RE, Willems JL, van den Bosch S, Schröder CH, et al. Intraperitoneal hypercoagulation and hypofibrinolysis is present in childhood peritonitis. Pediatr Nephrol 1999; 13:284-7.
14. Holmdahl L, Falkenberg M, Ivarsson ML, Risberg B. Plasminogen activators and inhibitors in peritoneal tissue. APMIS 1997; 105:25-30.
15. Nagase H, Ogata Y, Suzuki K, Enghild JJ, Salvesen G. Substrate specificities and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans 1991; 19:715-18.
16. Khasigov PZ, Podobed OV, Ktzoeva SA, Gatagonova TM, Grachev SV, Shishkin SS, et al. Matrix metalloproteinases of normal human tissues. Biochemistry (Mosc) 2001; 66:130-40.
17. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, et al. H-Ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988; 263:6579-87.
18. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264:17213-21.
19. Hirahara I, Inoue M, Okuda K, Ando Y, Muto S, Kusano E. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis-a multicentre study in Japan. Nephrol Dial Transplant 2007; 22:560-7.
20. Pannekeet MM, Imholz AL, Struijk DG, Koomen GC, Langedijk MJ, Schouten N, et al. The standard permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48:866-75.
21. Zemel D, Imholz AL, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46:1422-30.
22. Krediet RT, Sampimon DE, Vlijm A, Coester AM, Struijk DG, Smit W. Biological markers in the peritoneal dialysate effluent: are they useful. Contrib Nephrol 2009; 163:54-9.
23. Waniewski J, Werynski A, Heimbürger O, Lindholm B. Simple models for description of small-solute transport in peritoneal dialysis. Blood Purif 1991; 9:129-41.
24. Waniewski J, Heimbürger O, Werynski A, Lindholm B. Aqueous solute concentrations and evaluation of mass transport coefficients in peritoneal dialysis. Nephrol Dial Transplant 1992; 7:50-6.
25. Zweers MM, Imholz AL, Struijk DG, Krediet RT. Correction of sodium sieving for diffusion from the circulation. Adv Perit Dial 1999; 15:65-72.
26. Smit W, Struijk DG, Ho-Dac-Pannekeet MM, Krediet RT. Quantification of free water transport in peritoneal dialysis. Kidney Int 2004; 66:849-54.
27. La Milia V, Di Filippo S, Crepaldi M, Del Vecchio L, Dell'Oro C, Andrulli S, et al. Mini-peritoneal equilibration test: a simple and fast method to assess free water and small solute transport across the peritoneal membrane. Kidney Int 2005; 68:840-6.
28. Vlijm A, Sampimon DE, de Graaff M, Struijk DG, Krediet RT. Experimental peritoneal sclerosis models should not be based on chlorhexidine gluconate anymore. Nephron Exp Nephrol 2011; 117:e1-8.
29. Vlijm A, Sampimon DE, de Graaff M, Struijk DG, Krediet RT. A two-hit approach in the development of an experimental peritoneal sclerosis model. Adv Perit Dial 2012; 28:26-31.
30. Hirahara I, Inoue M, Umino T, Saito O, Muto S, Kusano E. Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: a multicentre study in Japan. Nephrol Dial Transplant 2011; 26:1695-701.
31. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11:S37-43.
32. Wilkins-Port CE, Freytag J, Higgins SP, Higgins PJ. PAI-1: a multifunctional SERPIN with complex roles in cell signaling and migration. Cell Commun Insights 2010; 3:1-10.
33. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West-Mays JA, et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16:425-36.
34. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21:1104-17.
35. Parikova A, Smit W, Struijk DG, Krediet RT. Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure. Kidney Int 2006; 70:1988-94.
36. Parikova A, Smit W, Zweers MM, Struijk DG, Krediet RT. Free water transport, small pore transport and the osmotic pressure gradient. Nephrol Dial Transplant 2008; 23:2350-5.
37. Zemel D, Koomen GC, Hart AA, ten Berge IJ, Struijk DG, Krediet RT. Relationship of TNF-alpha, interleukin-6, and prostaglandins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 1993; 122:686-96.
38. Rodrigues AS, Martins M, Korevaar JC, Silva S, Oliveira JC, Cabrita A, et al. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters. Am J Nephrol 2007; 27:84-91.
39. Mushahar L, Lambie M, Tan K, John B, Davies SJ. Long-term changes in solute and water transport. Contrib Nephrol 2009; 163:15-21.
40. Krediet RT, Zweers MM, van Westrhenen R, Zegwaard A, Struijk DG. Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD? NDT Plus 2008; 1(Suppl 4):iv56-iv62.